🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

INDEGENE LIMITED INDGN NIFTY_SMALLNSEPHARMA

Healthcare · Health Information Services · India
https://www.indegene.com
Company Profile ↓
₹511.75
-10.34% 1Y
Mkt Cap₹12,328.13 Cr
P/E30.79
P/B3.91
Div. Yield0.39%
52W High₹589.55
52W Low₹423.50
Book Value₹130.29
EPS (TTM)₹16.62

Company Overview

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.4%.

Consistent Profit Growth

Net profit has compounded at 14.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 30.8, below the sector median of 40.0.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹3,510.50 Cr (+23.6% YoY); net profit ₹401.10 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.6%, earnings -1.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.0%, profit CAGR 14.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.04%
1 Year:23.64%

Compounded Profit Growth

5 Years:14.66%
1 Year:-1.38%

Stock Price Performance

1 Year:-10.34%
6 Months:+0.36%
3 Months:+4.62%
1 Month:-0.36%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 53% of range
₹423.50 ₹589.55
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)50.15 · Neutral
Price Performance
1M-0.36%
3M+4.62%
6M+0.36%
1Y-10.34%
Valuation vs Sector

P/E of 30.79 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.0% over 5 years.
  • Profit CAGR of 14.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
30.79
Industry PE
39.97
Forward P/E
19.21
PEG Ratio
-
Book Value
₹130.29
Price to Book
3.91
P/S
3.51
EV/EBITDA
17.68
Dividend Yield
0.39%

Growth (CAGR)

Revenue 5Y
15.04%
Profit 5Y
14.66%
Revenue (YoY)
23.64%
Earnings (YoY)
-1.38%

Profitability & Returns

ROCE
15.40%
ROE
12.78%
ROA
8.68%
Profit Margin
11.43%
Op Margin
14.03%
Gross Margin
100.00%
EPS (Latest Qtr)
₹3.30
EPS (TTM)
₹16.62

Balance Sheet & Liquidity

Debt/Equity
4.60
Quick Ratio
2.27
Current Ratio
2.41
Debt
₹144.40 Cr
Total Assets
₹4,620.30 Cr
Current Assets
₹2,618.40 Cr
Working Capital
₹1,532.20 Cr

Ownership

Promoter Holding
55.67%
Chg in Prom Hold
-1.48%
FII / Inst Holding
20.32%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹12,328.13 Cr
Total Revenue (TTM)
₹3,510.50 Cr
EBITDA
₹670.80 Cr
Free Cash Flow
₹606.40 Cr
Operating Cash Flow
₹650.80 Cr
Shares Outstanding
₹24.09 Cr
Gross Margin
100.00%
Payout Ratio
12.03%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INDGN INDEGENE LIMITED NIFTY_SMALLNSEPHARMA 511.75 30.79 ₹12,328.13 Cr 0.39% 15.40% 12.78% 15.04% 14.66%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 632.00 Cr608.00 Cr636.00 Cr673.00 Cr673.00 Cr676.00 Cr-720.40 Cr755.60 Cr760.80 Cr804.00 Cr942.10 Cr1,003.40 Cr
Cost of Revenue -------------
Gross Profit -------------
Operating Expenses 535.00 Cr511.00 Cr515.00 Cr524.00 Cr534.00 Cr548.00 Cr-608.60 Cr628.80 Cr627.10 Cr664.00 Cr822.20 Cr881.60 Cr
Operating Income 77.00 Cr77.00 Cr101.00 Cr131.00 Cr121.00 Cr109.00 Cr-111.80 Cr126.80 Cr133.70 Cr118.00 Cr119.90 Cr121.80 Cr
EBITDA 97.00 Cr97.00 Cr121.00 Cr149.00 Cr139.00 Cr129.00 Cr-169.50 Cr173.10 Cr177.40 Cr141.00 Cr178.90 Cr154.10 Cr
Interest Expense 12.00 Cr13.00 Cr12.00 Cr12.00 Cr12.00 Cr12.00 Cr-3.20 Cr3.10 Cr3.70 Cr4.00 Cr4.60 Cr7.20 Cr
Pretax Income 79.00 Cr92.00 Cr101.00 Cr132.00 Cr134.00 Cr120.00 Cr-146.30 Cr149.30 Cr152.10 Cr133.00 Cr134.70 Cr105.10 Cr
Tax Provision 30.02 Cr23.92 Cr25.25 Cr33.00 Cr38.86 Cr32.40 Cr-36.60 Cr31.70 Cr35.70 Cr30.59 Cr31.80 Cr25.40 Cr
Net Income 49.00 Cr68.00 Cr75.00 Cr99.00 Cr95.00 Cr88.00 Cr-109.70 Cr117.60 Cr116.40 Cr102.00 Cr102.90 Cr79.70 Cr
Diluted EPS 2.203.083.384.454.263.67-4.554.884.824.254.263.30

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 553.00 Cr643.00 Cr966.00 Cr-2,306.10 Cr2,589.60 Cr2,839.30 Cr3,510.50 Cr
Cost of Revenue --------
Gross Profit --------
Operating Expenses 511.00 Cr499.00 Cr736.00 Cr-1,969.80 Cr2,154.80 Cr2,385.20 Cr3,017.90 Cr
Operating Income 25.00 Cr125.00 Cr204.00 Cr-336.30 Cr434.80 Cr454.10 Cr492.60 Cr
EBITDA 42.00 Cr144.00 Cr230.00 Cr-454.10 Cr581.00 Cr641.50 Cr670.80 Cr
Interest Expense 6.00 Cr9.00 Cr7.00 Cr-31.30 Cr46.30 Cr22.00 Cr19.30 Cr
Pretax Income 26.00 Cr14.00 Cr195.00 Cr-363.00 Cr458.60 Cr539.30 Cr525.00 Cr
Tax Provision 11.70 Cr26.74 Cr44.85 Cr-96.90 Cr121.90 Cr132.60 Cr123.90 Cr
Net Income 14.00 Cr-12.00 Cr149.00 Cr-266.10 Cr336.70 Cr406.70 Cr401.10 Cr
Diluted EPS 89.98-40.20951.96-11.1214.0917.0216.62

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 329.00 Cr600.00 Cr596.00 Cr-2,203.87 Cr2,545.60 Cr3,325.90 Cr4,620.30 Cr
Current Assets ----1,448.71 Cr1,790.80 Cr2,530.00 Cr2,618.40 Cr
Cash & Equivalents ----73.58 Cr188.60 Cr241.00 Cr300.80 Cr
Inventory --------
Receivables ----519.89 Cr555.70 Cr632.20 Cr770.20 Cr
Total Liabilities ----1,140.14 Cr1,116.50 Cr710.30 Cr1,481.60 Cr
Current Liabilities ----489.15 Cr610.90 Cr564.50 Cr1,086.20 Cr
Long Term Debt ---10.94 Cr394.34 Cr333.40 Cr0-
Total Debt 147.00 Cr483.00 Cr51.00 Cr-502.58 Cr489.60 Cr101.60 Cr144.40 Cr
Total Equity 73.31 Cr-104.69 Cr324.31 Cr-1,063.72 Cr1,429.10 Cr2,615.60 Cr3,138.70 Cr
Shares Outstanding ----23.89 Cr23.93 Cr24.00 Cr24.09 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 65.00 Cr22.00 Cr172.00 Cr-130.20 Cr507.70 Cr441.90 Cr650.80 Cr
Investing Cash Flow -18.00 Cr-16.00 Cr-81.00 Cr--893.30 Cr-327.20 Cr-682.70 Cr-512.40 Cr
Financing Cash Flow -21.00 Cr136.00 Cr-132.00 Cr-333.10 Cr-66.20 Cr287.50 Cr-82.60 Cr
Capital Expenditure -17.00 Cr-6.00 Cr-21.00 Cr--18.80 Cr-10.70 Cr-30.00 Cr-44.40 Cr
Free Cash Flow 48.00 Cr16.00 Cr151.00 Cr-111.40 Cr497.00 Cr411.90 Cr606.40 Cr
Net Change in Cash 25.00 Cr143.00 Cr-40.00 Cr--430.00 Cr114.30 Cr46.70 Cr55.80 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------
Operating Margin % 4.5%19.4%21.1%-14.6%16.8%16.0%14.0%
Net Margin % 2.5%-1.9%15.4%-11.5%13.0%14.3%11.4%
ROE % 19.1%11.5%45.9%-25.0%23.6%15.5%12.8%
ROCE % ----19.6%22.5%16.4%13.9%

Shareholding Pattern

Insiders
55.67%
Institutions
20.32%
Public Float
45.85%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDGN

Google News Mon, 13 Jul 2026

Indian shares recoup intraday losses as IT stocks shine - Reuters

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxONEQxNWtFdV9JXzY0RnUtVXhxNGE5RHlOMW1CRHhrQlBfTjNkck1qR0ZOUzg1ZXVfalNiVlUwczRaR2pWeXBkRlJwdzBtX25vSHJzdDNKT0FiOUJXMld0WTJucHZHN0xqSW1fSDlIY0kyUG5XMDJMV0RibTNkX3VYeHhxSllqNW5XWW5wNW…

Google News Mon, 13 Jul 2026

Foreign Investors Pump Over $1 Billion Into Indian Stock Market In A Week - NDTV

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQWWRLa1ozMFhQTTNDR1BiMmJRUldFWVNEVk9QR1k4UDBPelZMMFZ5WEVMUFFBQTFYSTFrNjVWTTdZWE5ZblV6alBsYW5FYUJqZVYtX09KYVNjVmRvZ2ppa2J1aWh3VWtHdVF6NkxDLWhfU3UwaE5VR3RCakFTd2p4a05YSHg0ck5nMnY3R2…

Google News ue, 14 Jul 2026

Indian stock markets rise on US-Iran peace deal hopes and lower oil prices - News On AIR

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxObnNVbGpWSlRSWUtBZXY2Y3loYWUza3Fvd2ZJY0NHLVdhZkw0aTdPcG41UDlxQXFjMWl1ajRvckhWZVJaWmx5U3RuTWg5dGdFcXhFRGxYaGlyaElOOUVqVGhOcl9QME4xSVZ2UVhUMmlNSlhOVFh2VDF1VkMtYnE5MTBpZzFITDN4Z011Sm…

Google News Mon, 22 Jun 2026

Global Funds Snap Indian Stock Selling Streak as Oil Shock Ebbs - Bloomberg.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNMXJra19GaG1qT0Zfa1ZJenpjSEpNanpmUnd5QUc4SVJlWUhhZTFFYVhTSllUQzFLaWFFTm80dHdPUnkxbzIwWTk5T080eXJLcFVsb1Z2QWU4cXdXYTVESHRfNW00aExORzh6VlhLWmduZGI5UkdvVTYyZ0Q3eWhnU1pjNWxBcHJORGpvR3…

Google News Fri, 19 Jun 2026

Indian IT stocks slump up to 7% as Accenture cuts revenue outlook, fueling fresh concerns over sector growth - CNBC

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQaWIyTmhWUzF5bmJDUGxRNllGWnRDdzQ4cFdwcXNyWTBvV3Z6RUJLLUk0cnBTaGRKYnJ0aVREQ2hFby1wb0RDcXRYNHdOOVJxZkxzbVBoUFRLWUJiRkNGTHRDdW14WmNaNHFVZjBYZDQzdzMtZ0tWRkNTVDBkZkctRVdUM1NHRTdlQUhvcE…

Google News ue, 30 Jun 2026

Global funds revisit Indian stocks as oil, rupee risks recede - Reuters

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMGJpTVFCa3dqd1BsOEZuaFc0eUJ4MU5NSC01Y3U1eXV1SXR4NURFZ1J3MWVaNm9QSWVvb2owempXY1EyX0MtbWw2QktDelJFaGt3ay0yOFlXUVRNbW8zYXp4Qm5YMTYyaG9BOXc3UTBPNktBZ1pOZjhUUGVWVGRkMUNxM1RuOG1KZlVnaV…

INDGN — Frequently Asked Questions

What is the current share price of INDEGENE LIMITED (INDGN)?

As of 2026-07-15 09:52 IST, INDEGENE LIMITED (INDGN) trades at ₹511.75 on NSE. Its 52-week range is ₹423.50 to ₹589.55.

What is the market capitalisation of INDGN?

INDEGENE LIMITED (INDGN) has a market capitalisation of ₹12,328.13 Cr on NSE.

What is the P/E ratio of INDGN?

INDGN trades at a trailing price-to-earnings (P/E) ratio of 30.79. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.91.

Does INDGN pay a dividend?

INDEGENE LIMITED (INDGN) currently offers a dividend yield of 0.39%.

What is the return on equity (ROE) of INDGN?

INDGN has a return on equity (ROE) of 12.78%. Its return on capital employed (ROCE) is 15.40%.

Is INDGN a good stock to buy?

This page provides a data-driven analysis of INDEGENE LIMITED (INDGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space